Diffusion Pharmaceuticals

139 articles with Diffusion Pharmaceuticals

• 

  Clinical Catch-Up: December 11-17

  12/20/2021

  It was an enormously busy week with plenty of announcements from the American Society of Hematology meeting and numerous companies working to get the news out ahead of the holidays and year-end. Here’s a look.

• Diffusion Pharmaceuticals Doses First Patients in ILD-DLCO TrialThird of Three TSC Oxygenation Trials

  12/16/2021

  Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that enhance the body’s ability to deliver oxygen to areas where it is needed most, today announced it has dosed the first patients in its ILD-DLCO Trial.

• Diffusion Pharmaceuticals Announces Issuance of U.S. Patent 11,185,523Claims Related to Use of TSC with Radiotherapy and Chemotherapy for Treatment of Cancer

  12/1/2021

  Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), today announced that it has been granted United States Patent No. 11,185,523, “Use of Bipolar Trans Carotenoids With Chemotherapy and Radiotherapy for Treatment of Cancer,” by the United States Patent and Trademark Office.

• 

  Clinical Catch-Up: November 22-26

  11/29/2021

  Thanksgiving week was marked by numerous clinical trial announcements. Here’s a look.

• Diffusion Pharmaceuticals Doses First Participants in Altitude Trial, Second of Three TSC Oxygenation Trials

  11/22/2021

  Diffusion Pharmaceuticals Inc today announced it has dosed the first participants in its Altitude Trial.

• Diffusion Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update

  11/10/2021

  Diffusion Pharmaceuticals Inc., a biopharmaceutical company developing novel therapies that enhance the body’s ability to deliver oxygen to areas where it is needed most, announced financial results for the third quarter of 2021 and provided a business update.

• Diffusion Pharmaceuticals to Participate in the Alliance Global Partners Biotech & Specialty Pharma Conference

  10/28/2021

  Diffusion Pharmaceuticals Inc. will participate in the 2021 Alliance Global Partners Biotech & Specialty Pharma Conference taking place November 10, 2021.

• Diffusion Pharmaceuticals Issues Letter to Shareholders

  9/9/2021

  Diffusion Pharmaceuticals Inc. today announced that Robert Cobuzzi, Jr., Ph.D., Chief Executive Officer, has issued a Letter to Shareholders.

• Diffusion Pharmaceuticals to Present at the 23rd Annual H.C. Wainwright Global Investment ConferenceConference to Take Place Virtually, September 13-15, 2021

  9/8/2021

  Diffusion Pharmaceuticals Inc. today announced that Robert Cobuzzi, Jr., Ph.D., Chief Executive Officer, will present at the H.C. Wainwright 23rd Annual Global Investment Conference taking place September 13-15, 2021.

• Diffusion Pharmaceuticals Announces Clearance of IND Application for TSC by FDA’s Pulmonology, Allergy, and Critical Care Division

  8/30/2021

  Diffusion Pharmaceuticals Inc. today announced that the Company has obtained clearance of its Investigational New Drug (IND) application submitted to the U.S. Food and Drug Administration’s (FDA) Pulmonology, Allergy, and Critical Care Division for the company’s lead product candidate, trans sodium crocetinate (TSC).

• Diffusion Pharmaceuticals Reports Q2 Financial Results and Provides Business Update

  8/11/2021

  Diffusion Pharmaceuticals Inc. today announced financial results for the second quarter of 2021 and provided a business update.

• Diffusion Pharmaceuticals Reports Positive Trend in Oxygenation from TCOM TrialTrial Dosed Healthy Volunteers with Trans Sodium Crocetinate

  6/30/2021

  Diffusion Pharmaceuticals Inc. today announced topline results from the Company’s Phase 1 trial of its lead product candidate, trans sodium crocetinate (“TSC”).

• Diffusion Pharmaceuticals to Webcast Live at Life Sciences Investor ForumPresentation Scheduled for June 24, 2021 at 11:30 a.m., EDT

  6/21/2021

  Diffusion Pharmaceuticals Inc. today announced that CEO Robert Cobuzzi, Jr., Ph.D., will present via webcast at the Life Sciences Investor Forum being held on June 24, 2021.

• Diffusion Pharmaceuticals Reminds Stockholders to Vote Shares In Advance of Annual MeetingAnnual Meeting Scheduled for June 25, 2021, at 1 p.m. EDT

  6/18/2021

  Diffusion Pharmaceuticals Inc. reminds stockholders to vote on the proposals listed in the Company’s proxy statement in advance of its upcoming annual meeting.

• Diffusion Pharmaceuticals Reports First Quarter Financial Results and Provides Business Update

  5/10/2021

  Diffusion Pharmaceuticals Inc., an innovative biopharmaceutical company developing novel therapies that enhance the body’s ability to deliver oxygen to areas where it is needed most, announced financial results for the first quarter of 2021 and provided a business update.

• Diffusion Pharmaceuticals Reports Final Results from Its Phase 1b Study of Trans Sodium Crocetinate in Hospitalized COVID-19 Patients

  5/10/2021

  Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN)  (“Diffusion” or the “Company”), an innovative biopharmaceutical company developing novel therapies that enhance the body’s ability to deliver oxygen to areas where it is needed most, today announced final results from the Phase 1b study evaluating trans sodium crocetinate (TSC) in hospitalized COVID-19 patients.  

• Diffusion Pharmaceuticals Completes Enrollment and Dosing in TCOM Study

  3/25/2021

  Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), an innovative biopharmaceutical company developing novel therapies that enhance the body’s ability to deliver oxygen to areas where it is needed most, today announced it has completed enrollment and dosing of all participants in the Company’s Phase 1 trial of its novel, oxygen enhancing therapeutic, trans sodium crocetinate (“TSC”)

• Diffusion Pharmaceuticals Doses First Participants in TCOM Study

  3/18/2021

  Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN)  (“Diffusion” or the “Company”), an innovative biopharmaceutical company developing novel therapies that enhance the body’s ability to deliver oxygen to areas where it is needed most, today announced that it has dosed the first participants in the Company’s Phase 1 trial of its novel, oxygen enhancing therapeutic, trans sodium crocetinate (“TSC”), utilizing a transcutaneous oxygen monitoring

• Diffusion Pharmaceuticals Reports 2020 Financial Results and Provides Business Update

  3/17/2021

  Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN)  (“Diffusion” or the “Company”), an innovative biopharmaceutical company developing novel therapies that enhance the body’s ability to deliver oxygen to areas where it is needed most, today announced financial results for 2020 and provided a business update.

• Diffusion Pharmaceuticals, Inc. to Present at the H.C. Wainwright Global Life Sciences Conference

  3/4/2021

  Diffusion Pharmaceuticals Inc., an innovative biopharmaceutical company developing novel therapies that enhance the body’s ability to deliver oxygen to areas where it is needed most, announced that Robert J. Cobuzzi, Ph.D., CEO of Diffusion, will present at the H.C. Wainwright Global Life Sciences Conference taking place March 9-10, 2021.